Breast cancer Non small cell lung cancer Paclitaxel Breast neoplasms Non-
Conditions
Interventions
Sponsors
Khumklao Foundation Under The Royal Patronage, Bhumibol Aduladej Hospital
Bangkok Drug Co. Ltd.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Informed consent Pathologic confirmed of breast cancer OR non-small-cell lung carcinoma Planned to receive at least 700mg per meter square of paclitaxel ECOG PS 0 - 2 Never received paclitaxel, docetaxel, cisplatin, carboplatin and oxaliplatin
Exclusion criteria
Exclusion criteria: Impaired liver or kidney function Presence of any grade peripheral neuropathy from any cause Presence of wound at hand or foot Presence of any condition that limit application of study drug Currently use gabapentin, Amitriptyline or Nortriptyline
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Grade D or more peripheral neuropathy - free rate (From Grade A to E) 4 weeks after last dose of chemotherapy Patient Neurotoxicity Questionnaire (Thai version) | — |
Secondary
| Measure | Time frame |
|---|---|
| Grade 2 or more peripheral neuropathy - free rate (From Grade 0 - 5) 4 weeks after last dose of chemotherapy Common Terminology Criteria of Adverse Events version 4.03,Time to develop any grade peripheral neuropathy Time from first date of chemotherapy to first date of any grade of peripheral neurpathy Patient Neurotoxicity Questionnaire (Thai version),Paclitaxel dose to develop any grade peripheral neuropathy Cumulative dose of paclitaxel that develop any grade of peripheral neurpathy Patient Neurotoxicity Questionnaire (Thai version),Adverse event From first date of chemotherapy to 4 weeks after last dose of chemotherapy Common Terminology Criteria of Adverse Events version 4.03 | — |
Countries
Thailand
Contacts
Public ContactSupachat Chompoonuch
Bhumibol Adulyadej Hospital
Outcome results
None listed